Adaptimmune Announces Changes to its Executive Leadership Team Based in The UKHelen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31,...
First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 2, 2024) - Adaptimmune Therapeutics plc (
NASDAQADAP), a company...
Adaptimmune Reports Q3 2024 Financial and Business UpdatesTecelra® launch on track with 9 Authorized Treatment Centers available to initiate patient treatment journey, and the first patient apheresed...
Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial42% of people with advanced or metastatic synovial sarcoma or MRCLS had clinical responses with lete-celResults include six complete responses...
Adaptimmune to Participate in Scientific and Medical Conferences this November and DecemberPhiladelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 5, 2024) - Adaptimmune Therapeutics plc (
NASDAQADAP), a company working...
Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 31, 2024) - Adaptimmune Therapeutics plc (
NASDAQADAP), a company redefining...
Life Sciences Virtual Investor Forum Presentations Now Available for Online ViewingCompany Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
Life Sciences Virtual Investor Forum Agenda Announced for September 19thCompany Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
Adaptimmune to Participate in Two Bank Conferences this SeptemberPhiladelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 28, 2024) - Adaptimmune Therapeutics plc (
NASDAQADAP), a company working to...
Adaptimmune Reports Q2 2024 Financial and Business UpdatesAdaptimmune received U.S. FDA accelerated approval of Tecelra® (afami-cel), the first approved engineered cell therapy for a solid tumorPatients can...
Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor
Adaptimmune Therapeutics plc (
NASDAQADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced U.S. Food and Drug Administration (FDA) accelerated approval of TECELRA® (afamitresgene autoleucel) for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. TECELRA is the first engineered cell therapy for a solid tumor cancer approved in the U.S., and the first new therapy option in more than a decade for synovial sarcoma, a rare, soft tissue cancer that most commonly impacts young adults.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) Advancing US FDA Process, Featured Among Top Health Care MoversIntelligent Bio Solutions Inc. (
NASDAQINBS), a medical technology company, offers rapid, intelligent, and non-invasive testing solutions. On May 29, the company announced its success in recruiting and starting the screening of subjects for its pharmacokinetic (PK) study. This study is a crucial step in Intelligent Bio Solutions' FDA 510(k) regulatory clearance process. The dedicated team worked diligently to ensure the study's design met FDA standards.
Adaptimmune Reports Q1 2024 Financial and Business UpdatesAfami-cel commercial and regulatory update presented at Company's Investor Day (replay HERE); FDA review and inspections progressing with PDUFA date...
Adaptimmune Secures up to $125 Million Debt Financing with Hercules CapitalPhiladelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 15, 2024) - Adaptimmune Therapeutics plc (
NASDAQADAP), a company redefining...
Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 1, 2024) - Adaptimmune Therapeutics plc (
NASDAQADAP), a company redefining...
Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the LancetPhiladelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - March 27, 2024) - Adaptimmune Therapeutics plc (
NASDAQADAP), a company redefining...
Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business UpdatesU.S. FDA accepted BLA for afami-cel for the treatment of advanced synovial sarcoma with priority review and a PDUFA date...
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma FranchisePhiladelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (
NASDAQADAP), a company redefining...
Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 21, 2024) - Adaptimmune Therapeutics plc (
NASDAQADAP), a company redefining...
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare ConferenceSarcoma franchise of afami-cel and lete-cel leverages same development and commercial footprint with US peak year sales projected to be...
